The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized Patients
Open accessAbstract
Background—: Identifying hospitalized patients at risk for QT interval prolongation could lead to interventions to reduce the risk of torsades de pointes. Our objective was to develop and validate a risk score for QT prolongation in hospitalized patients. Methods and Results—: In this study, in a single tertiary care institution, consecutive patients (n=900) admitted to cardiac care units comprised the risk score development group. The score was then applied to 300 additional patients in a validation group. Corrected QT (QT c ) interval prolongation (defined as QT c >500 ms or an increase of >60 ms from baseline) occurred in 274 (30.4%) and 90 (30.0%) patients in the development group and validation group, respectively. Independent predictors of QT c prolongation included the following: female (odds ratio, 1.5; 95% confidence interval, 1.1–2.0), diagnosis of myocardial infarction (2.4 [1.6–3.9]), sepsis (2.7 [1.5–4.8]), left ventricular dysfunction (2.7 [1.6–5.0]), administration of a QT-prolonging drug (2.8 [2.0–4.0]), ≥2 QT-prolonging drugs (2.6 [1.9–5.6]), or loop diuretic (1.4 [1.0–2.0]), age >68 years (1.3 [1.0–1.9]), serum K + <3.5 mEq/L (2.1 [1.5–2.9]), and admitting QT c >450 ms (2.3; confidence interval [1.6–3.2]). Risk scores were developed by assigning points based on log odds ratios. Low-, moderate-, and high-risk ranges of 0 to 6, 7 to 10, and 11 to 21 points, respectively, best predicted QT c prolongation (C statistic=0.823). A high-risk score ≥11 was associated with sensitivity=0.74, specificity=0.77, positive predictive value=0.79, and negative predictive value=0.76. In the validation group, the incidences of QT c prolongation were 15% (low risk); 37% (moderate risk); and 73% (high risk). Conclusions—: A risk score using easily obtainable clinical variables predicts patients at highest risk for QT c interval prolongation and may be useful in guiding monitoring and treatment decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
The long QT syndrome. Prospective longitudinal study of 328 families.
Moss, A. J., Schwartz, P. J., Crampton, R. S., Tzivoni, D., Locati, E. H., MacCluer, J., Hall, W. J., Weitkamp, L., Vincent, G. M., & Garson, A. (1991) · Circulation · doi:10.1161/01.cir.84.3.1136 · Cited by 968
Prolonged QTc Interval and Risk of Sudden Cardiac Death in a Population of Older Adults
Straus, S. M. J. M., Kors, J. A., De Bruin, M. L., van der Hooft, C. S., Hofman, A., Heeringa, J., Deckers, J. W., Kingma, J. H., Sturkenboom, M. C. J. M., Stricker, B. H. C., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.08.067 · Cited by 833
Drew, B. J., Ackerman, M. J., Funk, M., Gibler, W. B., Kligfield, P., Menon, V., Philippides, G. J., Roden, D. M., & Zareba, W. (2010) · Circulation · doi:10.1161/circulationaha.109.192704 · Cited by 821
Influence of the Genotype on the Clinical Course of the Long-QT Syndrome
Zareba, W., Moss, A. J., Schwartz, P. J., Vincent, G. M., Robinson, J. L., Priori, S. G., Benhorin, J., Locati, E. H., Towbin, J. A., Keating, M. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391404 · Cited by 754
Mechanism of the Cardiotoxic Actions of Terfenadine
Woosley, R. L. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500120070028 · Cited by 646
Roden, D. M., Woosley, R. L., & Primm, R. K. (1986) · American Heart Journal · doi:10.1016/0002-8703(86)90010-4 · Cited by 488
Viskin, S., Rosovski, U., Sands, A. J., Chen, E., Kistler, P. M., Kalman, J. M., Rodriguez Chavez, L., Iturralde Torres, P., Cruz F, F. E. S., Centurión, O. A., et al. (2005) · Heart Rhythm · doi:10.1016/j.hrthm.2005.02.011 · Cited by 409
Prevention of Torsade de Pointes in Hospital Settings
Drew, B. J., Ackerman, M. J., Funk, M., Gibler, W. B., Kligfield, P., Menon, V., Philippides, G. J., Roden, D. M., & Zareba, W. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.001 · Cited by 367
Gupta, A., Lawrence, A. T., Krishnan, K., Kavinsky, C. J., & Trohman, R. G. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.01.040 · Cited by 362
Torsade de Pointes Due to Noncardiac Drugs: Most Patients Have Easily Identifiable Risk Factors
Zeltser, D., Justo, D., Halkin, A., Prokhorov, V., Heller, K., & Viskin, S. (2003) · Medicine · doi:10.1097/01.md.0000085057.63483.9b · Cited by 273
Drug-induced long QT and torsade de pointes: recent advances
Kannankeril, P. J., & Roden, D. M. (2007) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32801129eb · Cited by 227
Torsade de pointes due to quinidine: Observations in 31 patients
Bauman, J. L., Bauernfeind, R. A., Hoff, J. V., Strasberg, B., Swiryn, S., & Rosen, K. M. (1984) · American Heart Journal · doi:10.1016/0002-8703(84)90081-4 · Cited by 208
Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes
DARPO, B. (2001) · European Heart Journal Supplements · doi:10.1016/s1520-765x(01)90009-4 · Cited by 205
Drug-induced diseases : prevention, detection, and management
Tisdale, J. E., & Miller, D. A. (2010) · Cited by 151
Self-citationSala, M., Vicentini, A., Brambilla, P., Montomoli, C., Jogia, J., Caverzasi, E., Bonzano, A., Piccinelli, M. P., Barale, F., & Ferrari, G. M. D. (2005) · Annals of General Psychiatry · doi:10.1186/1744-859x-4-1 · Cited by 145
Pickham, D. M., Helfenbein, E. D., Shinn, J. A., Chan, G. K., Funk, M., Weinacker, A. B., Liu, J., & Drew, B. J. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e318232db4a · Cited by 145
Reversible Myocardial Contraction Abnormalities in Patients With an Acute Noncardiac Illness
Sharkey, S. W., Shear, W. S., Hodges, M., & Herzog, C. A. (1998) · CHEST Journal · doi:10.1378/chest.114.1.98 · Cited by 134
Droperidol and Ondansetron-induced QT Interval Prolongation
Charbit, B., Alvarez, J., Dasque, E., Abé, E., Démolis, J., & Funck‐Brentano, C. (2008) · Anesthesiology · doi:10.1097/aln.0b013e31817fd8c8 · Cited by 127
In‐hospital cardiac arrest is associated with use of non‐antiarrhythmic QTc‐prolonging drugs
Bruin, M. L. D., Langendijk, P. N. J., Koopmans, R. P., Wilde, A. A. M., Leufkens, H. G. M., & Hoes, A. W. (2006) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02722.x · Cited by 120
Tisdale, J. E., Wroblewski, H. A., Overholser, B. R., Kingery, J. R., Trujillo, T. N., & Kovacs, R. J. (2012) · Drug Safety · doi:10.2165/11598160-000000000-00000 · Cited by 85
Self-citationHreiche, R., Plante, I., Drolet, B., Morissette, P., & Turgeon, J. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22437 · Cited by 16
Cited by
Mercuro, N. J., Yen, C. F., Shim, D. J., Maher, T. R., McCoy, C. M., Zimetbaum, P. J., & Gold, H. S. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1834 · Cited by 698
Schwartz, P. J., & Woosley, R. L. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.063 · Cited by 328
Brieger, D., Amerena, J., Attia, J., Bajorek, B., Chan, K. H., Connell, C., Freedman, B., Ferguson, C., Hall, T., Haqqani, H., et al. (2018) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2018.06.1043 · Cited by 327
Bader, F., Manla, Y., Atallah, B., & Starling, R. C. (2021) · Heart Failure Reviews · doi:10.1007/s10741-020-10008-2 · Cited by 259
Tisdale, J. E. (2016) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.1177/1715163516641136 · Cited by 209
Self-citation
Metadata
- Authors
- Tisdale, J. E., Jaynes, H. A., Kingery, J. R., Mourad, N. A., Trujillo, T. N., Overholser, B. R., & Kovacs, R. J.
- Venue
- Circulation: Cardiovascular Quality and Outcomes
- Published
- 2013-07
- Volume
- 6
- Issue
- 4
- Pages
- 479-487
- ISSN
- 1941-7705 (ISSN-L)
- 1941-7713
- OpenAlex
- W2022501241
- Cited by
- 385
- References
- 22
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.